Loading stock data…
SSII
$3.99-0.03 (-0.75%)
Market ClosedLast close May 1
SS Innovations International, Inc., together with its subsidiaries, operates as a commercial-stage surgical robotics company in India, Philippines, Indonesia, South America, Iraq, Cyprus, Oman, United Arab Emirates (UAE), Nepal, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
SS Innovations International, Inc. in the Healthcare sector is trading at $3.99. The stock is currently near its 52-week low of $3.02, remaining 32.8% below its 200-day moving average. Technical signals show oversold RSI of 13 and bearish MACD signal, explaining why SSII maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 13) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.99
Potential Upside
5%
Whystock Fair Value$4.19
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
SS Innovations International, Inc., together with its subsidiaries, operates as a commercial-stage surgical robotics company in India, Philippines, Indonesia, South America, Iraq, Cyprus, Oman, United Arab Emirates (UAE), Nepal, and internationally. ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$884.58M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.91
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-3.65%
Volume
Today's trading volume
113,190
Recent News
SS Innovations International, Inc. (SSII) Gains Approvals for SSi Mantra in Key Emerging Markets
We recently compiled a list of the 12 Penny Stocks with Insider Buying in 2026. SS Innovations International, Inc. is one of the best stocks with Insider buying on this list. TheFly reported on March 30 that SSII announced that its SSi Mantra surgical robotic system obtained regulatory approvals for multiple uses in Colombia, Oman, […]
SS Innovations ramps up in telesurgery; XCath robot treats stroke remotely
SS Innovations’ robot won approvals to perform telesurgery in Indonesia and the Philippines, while the first remote robotic mechanical thrombectomy to treat stroke was performed with XCath’s system.
Why SS Innovations (SSII) Is Up 10.8% After Telesurgery Milestone And Auditor Going Concern Doubts
SS Innovations International, Inc. recently reported that for the fourth quarter of 2025 its revenue rose to US$14.53 million while it recorded a net loss of US$2.47 million, and full-year 2025 revenue increased to US$42.48 million with a reduced net loss of US$12.13 million, although its auditor raised going concern doubts in the latest 10-K. Around the same time, the company announced that its SSi Mantra surgical robotic system has been cleared for telesurgeries in Indonesia and the...
SS Innovations raises $18.6M as surgical robot nears US market
Intuitive co-founder Fred Moll invested $2 million, supporting SS Innovations’ efforts to launch its robot in the U.S.
What SS Innovations International (SSII)'s 2025 Revenue Surge and Leadership Shift Means For Shareholders
SS Innovations International recently issued preliminary, unaudited guidance indicating fourth-quarter 2025 revenue of about US$15.0 million and full-year 2025 revenue of about US$43.0 million, both sharply higher than 2024 levels, alongside new product launches and senior leadership changes. An interesting angle for investors is the rapid build-out of the SSi Mantra surgical robot installed base, supported by new 5-millimeter instruments and an incoming Global Chief Operating Officer and...